(Total Views: 585)
Posted On: 12/09/2024 3:49:42 PM
Post# of 148870
In this post, Aligned En Route With End Game Heading , I say the following:
Scott Kelly said this in the >2 year old 3/31/22 Conference Call :
"Scott Kelly 12:45:
We've been contacted by academic institutions interested in doing studies with leronlimab. A researcher from a top university in Boston. CAR T research. CAR T not working as well against solid tumors as was hoped. For this study we will need to supply molecule only, (they will do trial). It is believed that the tumor micro environment is contributing to the lack of effectiveness of CAR T progress against solid tumors and we can control the tumor micro environment; we may be able to enhance the effectiveness of CAR T Therapy.
We have been contacted by the department of neurological surgery at a major academic center in NYC. and they are planning to evaluate leronlimab in glioblastoma multiforme which is a very aggressive brain tumor. Again, we will supply leronlimab and they've expressed their interest that if successful, in this non-clinical model, that they would pay for a human trial.
In the study in the use of check point inhibitors, which is funded by CytoDyn, it may represent another potential opportunity in immunotherapy and is moving forward.
We have been in contact in London with the university and foundation to further evaluate the potential of LL as a treatment in Alzheimer's. Their interest is in the role of neuro inflammation. It is similar to the role of cancer where initially people did not believe that cancer had an inflammatory component. I think the same is true in a number of central nervous system disorders.
We are also considering the potential of leronlimab acting as a long acting HIV PrEP agent in macaques. If successful, we are very excited about this. This has the potential to turn leronlimab into a once every 3 month injection from once per week. This could be future of HIV treatment with PrEP as a long acting injectable.
Possibility of a grant funded Phase 2 clinical trail in leronlimab with HIV patients with NASH & NAFLD, where we supply LL, but do not pay for the trial."
Notice the use of the word "Foundation", this time by Scott Kelly nearly 3 years ago?
Quote:
Still on Alzheimer's Disease, dfl28 at Investor's Hangout offers a suggestion for who this external source might be, but my lean is towards London's Imperial College Healthcare's Paul Edison, MD as I explain why here . Look at Scott Kelly's comments in the bulleted list below to see what is said about Alzheimer's Disease.
Scott Kelly said this in the >2 year old 3/31/22 Conference Call :
"Scott Kelly 12:45:
We've been contacted by academic institutions interested in doing studies with leronlimab. A researcher from a top university in Boston. CAR T research. CAR T not working as well against solid tumors as was hoped. For this study we will need to supply molecule only, (they will do trial). It is believed that the tumor micro environment is contributing to the lack of effectiveness of CAR T progress against solid tumors and we can control the tumor micro environment; we may be able to enhance the effectiveness of CAR T Therapy.
We have been contacted by the department of neurological surgery at a major academic center in NYC. and they are planning to evaluate leronlimab in glioblastoma multiforme which is a very aggressive brain tumor. Again, we will supply leronlimab and they've expressed their interest that if successful, in this non-clinical model, that they would pay for a human trial.
In the study in the use of check point inhibitors, which is funded by CytoDyn, it may represent another potential opportunity in immunotherapy and is moving forward.
We have been in contact in London with the university and foundation to further evaluate the potential of LL as a treatment in Alzheimer's. Their interest is in the role of neuro inflammation. It is similar to the role of cancer where initially people did not believe that cancer had an inflammatory component. I think the same is true in a number of central nervous system disorders.
We are also considering the potential of leronlimab acting as a long acting HIV PrEP agent in macaques. If successful, we are very excited about this. This has the potential to turn leronlimab into a once every 3 month injection from once per week. This could be future of HIV treatment with PrEP as a long acting injectable.
Possibility of a grant funded Phase 2 clinical trail in leronlimab with HIV patients with NASH & NAFLD, where we supply LL, but do not pay for the trial."
Notice the use of the word "Foundation", this time by Scott Kelly nearly 3 years ago?
(8)
(0)Scroll down for more posts ▼
